

Product Data Sheet

Product Name: Evogliptin tartrate

Cat. No.: GC60828

Chemical Properties

Cas. No. 1222102-51-3

SMILES O=C1NCCN(C(C[C@H](N)CC2=CC(F)=C(F)C=C2F)=O)[C@@H]1COC(C)(C)C.O=C(O)[C@H](O)[C@@H](O)C(O)=O


Formula $C_{23}H_{32}F_3N_3O_9$ M.Wt 551.51

Solubility DMSO: 100 mg/mL (181.32 mM) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity. Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Evogliptin tartrate significantly inhibits the TNF- α -mediated induction of ICAM-1 and VCAM-1 expression in a concentration-dependent manner (IC₅₀ = 0.30 and 0.25 μ M, respectively) [1]. Evogliptin tartrate inhibits the TNF- α -mediated transcriptional activation of ICAM-1 and VCAM-1 [1]. Evogliptin tartrate inhibits inflammatory responses via suppression of adhesion molecules induced by TNF- α . And TNF- α -mediated activation of NF- κ B is ameliorated by evogliptin via the interaction of NF- κ B with SIRT1 [1]. Cell Viability Assay [1] Cell Line: Endothelial cells

Evogliptin tartrate (37.5-150 mg/kg; p.o.; daily; for 12 weeks) reduces the high-fat diet-induced atherosclerotic plaque area in the ApoE^{-/-} mouse model [1]. Evogliptin tartrate inhibits the formation of atherosclerotic lesions by reducing vasoinflammation and increases plaque stability [1]. Animal Model: ApoE^{-/-} mice [1]

[1]. Modulation of Sirt1/NF- κ B interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation. Biochem Pharmacol. 2019 Oct;168:452-464.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA